Oncocross Co., Ltd. (KOSDAQ:382150)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,070.00
+70.00 (1.00%)
Mar 12, 2026, 2:03 PM KST
Market Cap85.37B -36.6%
Revenue (ttm)884.68M +103.0%
Net Income-8.33B
EPS-716.67
Shares Out12.20M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume39,108
Average Volume404,267
Open7,000.00
Previous Close7,000.00
Day's Range6,940.00 - 7,170.00
52-Week Range6,150.00 - 16,700.00
Betan/a
RSI40.06
Earnings DateMar 20, 2026

About Oncocross

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular D... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 382150
Full Company Profile

Financial Performance

In 2024, Oncocross's revenue was 1.07 billion, an increase of 1071.49% compared to the previous year's 91.52 million. Losses were -6.48 billion, 53.8% more than in 2023.

Financial Statements